Core Viewpoint - The approval of "Longpei Growth Hormone," a long-acting growth hormone injection, marks a significant development in the market for growth hormone treatments in China, aiming to address the needs of children with growth hormone deficiency [2][3]. Group 1: Product Overview - "Longpei Growth Hormone" is the fourth long-acting growth hormone approved for sale in China, following its approval in the US and EU four years ago [2]. - The product requires only one injection per week, contrasting with short-acting versions that require daily injections [2]. - The product is positioned in the mid-to-high-end market, with the company emphasizing a focus on quality rather than engaging in price wars [2][3]. Group 2: Market Dynamics - The introduction of long-acting growth hormones into the National Medical Insurance Directory is expected to enhance accessibility, with prices potentially dropping by about 50% after insurance coverage [3]. - The market is evolving into two segments: "insurance-inclusive" and "high-end quality," with the company targeting the unmet demand in the mid-to-high-end segment [3][4]. - The company has established partnerships with major distributors and healthcare providers to ensure effective market penetration and reach [3]. Group 3: Clinical and Storage Advantages - "Longpei Growth Hormone" has demonstrated superior efficacy in clinical trials, showing a statistically significant increase in annual growth rate compared to traditional daily injections, potentially offering an additional height gain of approximately 1 cm per year [4]. - The product can be stored at room temperature for up to six months without preservatives, providing a logistical advantage over other long-acting growth hormones that require refrigeration [5].